Royalty Pharma PLC (NAS:RPRX)
$ 26.66 0.06 (0.23%) Market Cap: 11.85 Bil Enterprise Value: 17.69 Bil PE Ratio: 10.45 PB Ratio: 1.73 GF Score: 81/100

Royalty Pharma PLC at UBS Global Healthcare Virtual Conference Transcript

May 24, 2021 / 06:00PM GMT
Release Date Price: $40.72 (+0.05%)
Navin Cyriac Jacob
UBS Investment Bank, Research Division - Equity Research Analyst of Specialty Pharmaceuticals and Large Cap Pharmaceutic

(technical difficulty) pharma and biotech here at UBS. Thank you for joining us today this afternoon. Our next presentation is from Royalty Pharma whom I cover. I'm happy to have with us Terry Coyne, Chief Financial Officer; Marshall Urist, EVP and Co-Head of Research and Investments; and George Grofik, SVP, Head of Investor Relations and Communications.

So we're going to have about 15 to 20 minutes of slides and presentation. Just for folks who aren't as familiar with Royalty, it's a great way to learn it. And then after that, about 30 minutes of Q&A from myself moderating that.

And from you all, if you want to pose questions, please feel free to do so online on this program, and they will be anonymous and I will read them out.

And without further ado, let me turn it over to Royalty, and Terry or Marshall, please go ahead.

Terrance Coyne
Royalty Pharma plc - Executive VP & CFO

Great.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot